Pathological response as prognostic indicator for recurrence and survival in early triple negative breast cancer (eTNBC) – use case for multi-centre RWD to support patient access
Innovative new medicines used in conjunction with neoadjuvant chemotherapy (NACT) may lead to a higher pathological complete response (pCR), and therefore a better chance of survival for patients diagnosed with eTNBC cancer. The Edinburgh Cancer Informatics, in partnership with DATA-CAN, ran a retrospective, longitudinal cohort study using routinely collected data to better describe differences in […]